Objective: To assess the effect of oral cannabidiol (CBD) administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with idiopathic epilepsy.
Design: Randomized blinded controlled clinical trial.
Animals: 26 client-owned dogs with intractable idiopathic epilepsy.
Procedures: Dogs were randomly assigned to a CBD (n = 12) or placebo (14) group. The CBD group received CBD-infused oil (2.5 mg/kg [1.1 mg/lb], PO) twice daily for 12 weeks in addition to existing antiepileptic treatments, and the placebo group received noninfused oil under the same conditions. Seizure activity, adverse effects, and plasma CBD concentrations were compared between groups.
Results: 2 dogs in the CBD group developed ataxia and were withdrawn from the study. After other exclusions, 9 dogs in the CBD group and 7 in the placebo group were included in the analysis. Dogs in the CBD group had a significant (median change, 33%) reduction in seizure frequency, compared with the placebo group. However, the proportion of dogs considered responders to treatment (≥ 50% decrease in seizure activity) was similar between groups. Plasma CBD concentrations were correlated with reduction in seizure frequency. Dogs in the CBD group had a significant increase in serum alkaline phosphatase activity. No adverse behavioral effects were reported by owners.
Conclusions and clinical relevance: Although a significant reduction in seizure frequency was achieved for dogs in the CBD group, the proportion of responders was similar between groups. Given the correlation between plasma CBD concentration and seizure frequency, additional research is warranted to determine whether a higher dosage of CBD would be effective in reducing seizure activity by ≥ 50%.
Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for EpilepsyMS Perry. Epilepsy Curr 19 (2), 93-95. PMID 30955420.Among children and adults with the Lennox-Gastaut syndrome, the addition of cannabidiol at a dose of 10 or 20 mg/kg/d to a conventional antiepileptic regimen resulted in …
Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients With Developmental and Epileptic EncephalopathyN Pietrafusa et al. Paediatr Drugs 21 (4), 283-290. PMID 31179531.These data suggest that CBD may have beneficial effects in patients with DEE and an acceptable safety profile. Placebo-controlled randomized trials should be conducted to …
Lamotrigine Adjunctive Therapy Among Children and Adolescents With Primary Generalized Tonic-Clonic SeizuresE Trevathan et al. Pediatrics 118 (2), e371-8. PMID 16847080. - Randomized Controlled TrialAdjunctive lamotrigine therapy seems effective in controlling primary generalized tonic-clonic seizures among patients 2 to 20 years of age.
Levetiracetam Add-On for Drug-Resistant Focal Epilepsy: An Updated Cochrane ReviewGK Mbizvo et al. Cochrane Database Syst Rev (9), CD001901. PMID 22972056. - ReviewThis update adds seven more trials to the original review, which contained four trials. At every dose analysed, levetiracetam significantly reduced focal seizure frequenc …
Cannabis for the Treatment of Epilepsy: An UpdateTE Gaston et al. Curr Neurol Neurosci Rep 18 (11), 73. PMID 30194563. - ReviewWhile the anticonvulsant mechanism of action of CBD has not been entirely elucidated, we discuss the most recent data available including its low affinity for the endocan …
Cited by 1 PubMed Central articles
Single-Dose Pharmacokinetics and Preliminary Safety Assessment With Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and CatsKA Deabold et al. Animals (Basel) 9 (10). PMID 31635105.The use of CBD-rich hemp products is becoming popular among pet owners with no long-term safety data related to consumption in adult dogs and cats. The purpose of this st …